Amarin Corporation plc (AMRN) News
Follow Amarin Corporation plc (AMRN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Amarin Reports Fiscal Q3 Net Loss
Amarin reported a fiscal 2026 third-quarter net loss attributable to shareholders, up 52.32% year over year. Basic EPS was negative.
EQUITY | Oct 29, 2026, 08:22 AM UTC
L
Amarin Reports Results for Quarter Ended September 30
Amarin reported results for the quarter ended September 30.
EARNINGS | Oct 28, 2026, 02:11 PM UTC
M
Amarin Q3 Revenue Falls 20% on US Pricing Pressure
EQUITY | Oct 28, 2026, 11:23 AM UTC
M
Amarin reports Q3 non-GAAP earnings of $0.08 per ADS
EQUITY | Oct 28, 2026, 11:20 AM UTC
M
Amarin Returns to Profit in Q3 2026 as Net Sales Fall
Amarin returned to profitability in Q3 2026, while net sales declined year over year.
EARNINGS | Oct 28, 2026, 11:15 AM UTC
M
Amarin Reports Q3 2026 Net Income of $245,000
Amarin swung to net income of $245,000 in Q3 2026, compared with a loss a year earlier.
EARNINGS | Oct 28, 2026, 11:15 AM UTC
M
Amarin Reports Third-Quarter Revenue of $39.6 Million
EQUITY | Oct 28, 2026, 11:13 AM UTC
L
AMRN presents REDUCE-IT legacy analysis at ESC 2026
AMRN presented new REDUCE-IT legacy analysis at the European Society of Cardiology (ESC) Congress 2026 on persistent cardiovascular benefit after icosapent ethyl cessation in adherent patients.
GEOPOLITICS | Aug 28, 2026, 12:15 PM UTC
H
AMRN - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 - Cli
AMRN - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
GEOPOLITICS | Aug 24, 2026, 12:15 PM UTC
L
JPMorgan initiates AMRN at Underweight with $13.00 target
JPMorgan initiates AMRN with an Underweight rating and a $13.00 price target.
EQUITY | Aug 21, 2026, 11:58 AM UTC
L
AMRN - Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy
AMRN - Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
EARNINGS | Jul 29, 2026, 11:01 AM UTC
H
serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - CGAU, OI, FCF, RCKY, RPT, APAM, GEHC, PB, VFC, OG
serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - CGAU, OI, FCF, RCKY, RPT, APAM, GEHC, PB, VFC, OGE, SITE, ARCC, BTU, STRA, MNRO, MCHB, RDWR, SHEN, AMRN
EARNINGS | Jul 28, 2026, 04:09 PM UTC
L
Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As
Amarin Corporation plc (NASDAQ: AMRN ), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3) therapies for the trea
REGULATION | Jun 30, 2026, 08:18 PM UTC